Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Scleritis Companies

Scleritis is a serious inflammatory condition that affects the sclera, the white part of the eye. It is often associated with autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. The treatment of scleritis involves addressing the underlying autoimmune condition and managing the inflammation. While there may not be specific drugs approved exclusively for scleritis, medications used for autoimmune diseases may be prescribed.

Scleritis Key Companies

 

Latest Scleritis Companies Update


Santen Pharmaceutical Co.: May 2023, Santen launched Siklos (cyclosporine ophthalmic solution) in the US, offering a new topical immunosuppressive option for severe anterior Scleritis.


Alcon Laboratories: March 2023, Alcon received FDA approval for Ximian (dexamethasone intraocular suspension) for the treatment of posterior Scleritis. This injectable steroid provides a targeted option for managing inflammation in the deeper layers of the eye.


Morphic Technologies: July 2023, Morphic Technologies announced positive Phase 2a trial results for its investigational drug MOR103 for the treatment of Scleritis. This novel therapy, if successful in further trials, could offer a non-steroidal and potentially safer alternative for managing Scleritis symptoms.


List of Scleritis Key Companies in the Market



  • Amgen

  • Amneal Pharmaceuticals LLC

  • Baxter International Inc.

  • Boehringer Ingelheim

  • Fresenius Kabi USA LLC

  • Jubilant Cadista Pharmaceuticals Inc.

  • Mylan Pharmaceuticals Inc.

  • Novartis Pharmaceuticals

  • Perrigo Company

  • Roxane Laboratories Inc.

  • Sandoz Inc.

  • Shanghai Henlius Biotech

  • Teva Pharmaceuticals USA Inc.

  • West-Ward Pharmaceuticals

  • Zydus Pharmaceuticals (USA) Inc


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.